Clinical Trials

Phase 2 Not yet recruiting

325 enrolled 14 charts

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Lymphoid

Hodgkin Disease

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Phase 2 Recruiting

184 enrolled

Breast Neoplasms

NCT06459180 2026-03-13

TroFuse-020

Phase 3 Recruiting

686 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Phase 2 Recruiting

90 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

342 enrolled

Sarcoma

Rhabdomyosarcoma

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

376 enrolled

Breast Neoplasms

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

502 enrolled 18 charts 1 FDA

Lung Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

Gynecologic

Uterine Cervical Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Phase 2 Not yet recruiting

108 enrolled

Lung Diseases, Interstitial

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

400 enrolled

Breast Neoplasms, Recurrence

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT07007559 2026-02-03

ASPEN-09

Phase 1/2 Recruiting

80 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04648033 2026-01-29

ARCADIAN

Phase 1 Completed

21 enrolled 21 charts

Locally Advanced Non-Small Cell Lung Cancer

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

122 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06564844 2026-01-27

TROPION-Lung12

24 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

350 enrolled

Triple Negative Breast Neoplasms

NCT06576635 2026-01-20

LUNG-05

Phase NA Recruiting

29 enrolled

Phase 2 Active not recruiting

NSCLC

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

300 enrolled

505 enrolled 17 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

45 enrolled